Lifeforce is Licensed and Regulated by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Human Tissue Authority (HTA). The Company is also Registered by the US Food and Drug Administration, FDA.  No other commercial organisation holds this level of Regulatory Licences for the production of human cells and tissues.

Human cells and tissues are used to treat many diseases including cancer, leukaemia, heart disease, infection, stroke, skin, bone and cartilage repair, blindness, chronic inflammation and diabetes.  Unlike most drugs, which alleviate the symptoms of disease (palliative), cell-based medicines provide curative therapies. These cell and tissue-based treatments are commonly referred to as Regenerative Medicines. 

Lifeforce provides Regulated cell and tissue services and products to academics, clinicians and the pharmaceutical industry.  It has created platform technologies which enable the industrial delivery of human cells and tissues for all forms of Regenerative Medicine.

In addition to licensing Regenerative Medicine Engine (RME) modules for Regenerative Medicine therapies, a number of services and technology products have emerged from Lifeforce R&D.  Lifeforce has used the RME to create the world's first Immune System Bank, where clients deposit their pristine immune cells as an insurance therapy against future serious diseases (cancers, leukaemias, sarcomas) and infections (CMV, Hep B/C, HIV/AIDS).